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The manufacturer of a linear accelerator (LINAC) has reported that the target melting phenomenon 
could be caused by a non-recommended output setting and the excessive use of monitor unit 
(MU) with intensity-modulated radiation therapy (IMRT). Due to these reasons, we observed an 
unexpected beam interruption during the treatment of a patient in our institution. The target status 
was inspected and a replacement of the target was determined. After the target replacement, the 
beam profile was adjusted to the machine commissioning beam data, and the absolute doses-to-
water for 6 MV and 10 MV photon beams were calibrated according to American Association of 
Physicists in Medicine (AAPM) Task Group (TG)-51 protocol. To verify the beam data after target 
replacement, the beam flatness, symmetry, output factor, and percent depth dose (PDD) were 
measured and compared with the commissioning data. The difference between the referenced and 
measured data for flatness and symmetry exhibited a coincidence within 0.3% for both 6 MV and 
10 MV, and the difference of the PDD at 10 cm depth (PDD10) was also within 0.3% for both photon 
energies. Also, patient-specific quality assurances (QAs) were performed with gamma analysis 
using a 2-D diode and ion chamber array detector for eight patients. The average gamma passing 
rates for all patients for the relative dose distribution was 99.1%±1.0%, and those for absolute dose 
distribution was 97.2%±2.7%, which means the gamma analysis results were all clinically 
acceptable. In this study, we recommend that the beam characteristics, such as beam profile, 
depth dose, and output factors, should be examined. Further, patient-specific QAs should be 
performed to verify the changes in the overall beam delivery system when a target replacement is 
inevitable; although it is more important to check the beam output in a daily routine.
Keywords: Linear accelerator, Target degradation, Target melting, Beam verification, IMRT 
verification
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Introduction
A linear accelerator (LINAC) is one of the most fre-
quently used radiotherapy machines in which the acceler-
ated electron collides with a tungsten target to generate 
the photon beam. According to a technical bulletin of the 
vendor (Varian Medical Systems, Palo Alto, CA, USA), they 
reported that the target in LINAC was melted or punctured 
in several institutes due to the excessive usage of moni-
tor unit (MU) with intensity-modulated radiation therapy 
(IMRT) and with non-recommended output calibration 
setting (1 cGy/MU at a depth of 10 cm instead of a depth 
Progress in Medical Physics  29(3), September 2018
https://doi.org/10.14316/pmp.2018.29.3.92
eISSN 2508-4453
PMP 
Progress in Medical Physics   Vol. 29, No. 3, September 2018 93
www.ksmp.or.kr
of maximum dose (dmax)). To prevent the target burning 
and degradation, the manufacturer established the target 
current monitoring system. The main role of this system is 
to interrupt the beam delivery when it goes over a certain 
tolerance level.
Therapists in our Institute experienced unusual frequent 
beam interrupts during patient treatment with target 
current monitoring system and interlock warning. The 
inspection followed immediately by beam output check 
by varying the position of electron-target hit and the maxi-
mum beam deviation was shown to be 3.8%. Technologists 
concluded that the target was punctured with burning, and 
physicists decided to replace the target. The damaged tar-
get was shown in Fig. 1.
In this study, we performed the beam verification to 
validate the clinically acceptable machine performance 
after the target replacement. Also, we measured beam flat-
ness, symmetry, output factor, and PDD after fine beam 
adjustment, also a patient-specific quality assurance (QA) 
analysis for the end-to-end machine performance verifica-
tion was performed.1-3) Safety issue caused by the activated 
target was carefully concerned.
Materials and Methods
1. Beam tuning
After the target assembly replacement, the beam pro-
files were finely adjusted to the reference beam data. To 
measure the beam profile, we used the three-dimensional 
water phantom (Blue Phantom2, IBA dosimetry, Schwar-
zenbruck, Germany) plotting tank and two CC13 compact 
ionization chamber (IBA dosimetry, Schwarzenbruck, 
Germany) as a reference and field chamber, respectively. 
The common control unit (CCU, IBA dosimetry, Schwar-
zenbruck, Germany) and myQA Accept software (ver 8.0., 
IBA dosimetry, Schwarzenbruck, Germany) was used. Note 
that we verified the beam profiles for 6 MV and 10 MV pho-
ton beams as targets of two photon energies were sealed in 
a single vacuum tube with assemblies.
Beam profiles measured at initial machine commission-
ing were used as reference data. The measurement condi-
tion was as follows: source-to-surface distance (SSD) of 
100 cm, reference depth of 10 cm, and field size of 35×35 
cm2. For each energy, the beam profile was finely adjusted 
to achieve the maximum difference between measurement 
and reference beam data less than 1%.
After adjusting the beam profile, output was calibrated 
for 6 MV and 10 MV by using 0.6 cc Farmer-type chamber 
(TN 30013, PTW-Freiburg, Freiburg, Germany) according 
to American Association of Physicists in Medicine (AAPM) 
Task Group (TG)-51 protocol, which is a global standard 
for clinical reference dosimetry of linear accelerators.4,5)
The output was calibrated to deliver 1 cGy/MU with ref-
erence conditions; SSD of 100 cm, field size of 10×10 cm2, 
and at dmax.
2. Verification
According to the manufacturers beam commissioning 
guide, we performed the mandatory PDD measurement 
where the SSD of 100 cm and field size of 3×3, 6×6, 10×10, 
20×20 cm2 for each energy. We compared the coincidence 
between measurement and reference data with dmax and 
the PDD at 10 cm (PDD10).
Crossline beam profiles were measured at SSD of 100 cm 
with field sizes of 3×3, 6×6, 10×10 and 20×20 cm2 at depth 
of dmax, 5, 10, 20 and 30 cm. They were compared with ma-
chine commissioning data of field sizes mentioned above, 
at 10 cm depth. Both maximum differences in crossline 
and inline profiles, and flatness and symmetry were com-
pared.Fig. 1. The punched tungsten target.
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Output factors were measured at SSD of 90 cm and depth 
of 10 cm, according to equation (1).
Output factor=
output of field size X×Y cm2
 (1)
output of field size 10×10 cm2
The reference field size was 10×10 cm2, and the field size 
varied from 3×3 cm2 to 40×40 cm2. Measured output factors 
were compared with reference data.
The patient-specific QA is the procedure to verify the 
coincidence between measurement and calculated dose 
distribution for IMRT plans by using gamma analysis.6) 
Eight IMRT plans for breast cancer patients using both 6 
MV and 10 MV were involved for verification. Two types of 
detectors were used; two‐dimensional ionization chamber 
array detector (MatriXX, IBA dosimetry, Schwarzenbruck, 
Germany) and diode array detector (MapCHECK2, Sun 
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Table 1. Percent depth dose at depth 10 cm (PDD10) comparisons between reference and measurement for 6 MV and 10 MV photon 
beam.
Field Size  
(cm2)
6 MV 10 MV
Reference Measured Difference Reference Measured Difference
3×3 61.3% 61.3% 0.0% 71.1% 71.2% 0.1%
6×6 64.6% 64.5% −0.1% 73.0% 73.3% 0.3%
10×10 67.3% 67.3% 0.0% 74.4% 74.6% 0.2%
20×20 70.1% 70.4% 0.3% 75.9% 76.0% 0.1%
40×40 72.7% 72.8% 0.1% 77.3% 77.5% 0.2%
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Nuclear Corp., Melbourne, FL, USA). Since the absolute 
dose calibration was performed with only MapCHECK2, 
MatriXX was used to verify the relative dose distribution 
while MapCHECK2 was used for the absolute dose distri-
bution. Gamma analysis between calculated and measured 
data of both detectors was performed by using SNC Patient 
software (Sun Nuclear Corporation, Melbourne, FL). Gam-
ma criteria of 3%/3 mm with dose threshold of 10% were 
used to analyze the coincidence between calculated and 
measured dose.
Results
1. Beam tuning
As shown in Fig. 2, the maximum deviations of the beam 
profile were adjusted within 0.77% and 0.94% and field 
width differences were 0.32 mm and 0.07 mm for 6 MV and 
10 MV, respectively.
When the beam output of each energy was adjusted to 
deliver 1 cGy/MU with reference conditions (SSD of 100 
cm, field size of 10×10 cm2, and at dmax), the output devia-
tion between before and after target replacement was 6.78% 
and 2.66% for 6 MV and 10 MV, respectively.
2. Verification
As shown in Table 1, the differences in PDD10 between 
reference and measurement were less than 0.3% for both 6 
MV and 10 MV. As presented in Fig. 3 for PDD comparison 
with a field size of 10×10 cm2, the differences at dmax be-
tween measurement and reference data were less than 0.5 
mm and 0.7 mm and the PDD10 were 0.04%, 0.22% for 6 MV 
and 10 MV, respectively.
The profile coincidences were compared with flatness 
and symmetry, and results were provided in Table 2. For 6 
MV, the flatness and symmetry showed good coincidence 
for 6×6 cm2, 10×10 cm2, and 20×20 cm2 showing less dif-
ference than 0.3% and 0.5%, while those for 3×3 cm2 were 
slightly higher showing −0.7% and −0.6%, respectively. For 
10 MV, the differences were less than −0.4% and −0.5%, 
while those for 3×3 cm2 were slightly higher showing −0.8% 
and −0.8%, respectively.
Table 3 showed the output factors for various field 
Table 3. Output factors comparison between reference and measurement data for 6 MV and 10 MV photon beams.
Field Size 6 MV 10 MV
X (cm) Y (cm) Reference Measured Difference Reference Measured Difference
3 3 0.830 0.832 0.23% 0.849 0.851 0.21%
3 10 0.889 0.894 0.51% 0.905 0.911 0.59%
3 40 0.924 0.930 0.58% 0.936 0.944 0.76%
5 5 0.895 0.895 −0.03% 0.914 0.915 0.14%
5 15 0.960 0.963 0.26% 0.970 0.973 0.30%
7 7 0.945 0.944 −0.10% 0.955 0.956 0.12%
7 20 1.009 1.011 0.21% 1.009 1.011 0.24%
10 3 0.879 0.879 −0.05% 0.894 0.894 −0.02%
10 10 1.000 1.000 0.00% 1.000 1.000 0.00%
10 30 1.066 1.067 0.15% 1.053 1.055 0.19%
15 5 0.947 0.945 −0.20% 0.954 0.953 −0.05%
15 15 1.063 1.062 −0.13% 1.047 1.046 −0.08%
15 40 1.123 1.125 0.22% 1.097 1.097 −0.04%
20 7 0.995 0.994 −0.14% 0.991 0.991 0.03%
20 20 1.105 1.104 −0.07% 1.077 1.076 −0.08%
30 10 1.050 1.050 −0.01% 1.035 1.035 −0.05%
30 30 1.163 1.163 0.00% 1.121 1.121 0.02%
40 3 0.899 0.898 −0.12% 0.909 0.908 −0.11%
40 15 1.107 1.107 −0.04% 1.077 1.077 0.04%
40 40 1.200 1.204 0.38% 1.153 1.154 0.07%
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sizes ranging from 3×3 cm2 to 40×40 cm2. The means and 
standard deviations of output factor differences between 
reference and measurement were 0.08%±0.22% and 
0.11%±0.22% for 6 MV and 10 MV, respectively. The maxi-
mum differences occurred at field size of 3×40 cm2 showing 
0.58% for 6 MV and 0.76% for 10 MV, respectively.
Fig. 4 showed the sample gamma analysis between cal-
culated and measurement. The gamma passing rates for 
absolute dose distribution were 97.2%±2.7% and those for 
relative dose distribution were 99.1%±1.0%. The gamma 
analysis results for each patient are presented in Table 4.
Discussion
After the target assembly replacement, the beam output 
was tuned and the absolute dose calibration was per-
formed according to AAPM TG-51 protocol. The beam 
was steered to the reference beam data. All verification pa-
rameters such as the profile, PDD and output factor were 
within tolerance level based on AAPM TG-142 protocol 
and recommended manufacturer’s guidance.7,8)
The gamma passing rates for 8 patients after the target re-
placement were 97.2%±2.7% for absolute dose distribution, 
and 99.1%±1.0% for relative dose distribution, respectively. 
Li et al.9) reported the impact of detector types in gamma 
passing rates with a diode-based array (MapCHECK2) and 
an ion chamber-based array (MatriXX) detector for the QA 
of IMRT treatment plans. It has shown that they obtained 
outstanding gamma passing rates for both detector arrays 
when compared with the dose distribution of the treatment 
planning system for three IMRT fields. For gamma pass-
ing rate, many radiation oncology clinics have commonly 
employed 3%/3 mm with a threshold level of 10%, which 
Fig. 4. Sample gamma analysis gra-
phical user interface (GUI) provided 
by SNC Patient software (Sun Nuclear 
Corporation, Melbourne, FL) for 
veri fi cation of intensity-modulated 
ra diation therapy (IMRT) plan.
Table 4. Gamma passing rates for eight patients with two types of 
detectors.
Patient Energy
MapCHECK2 
(*Abs.)
MatriXX (†Rel.)
Patient 1 6X 92.9% 98.4%
Patient 2 10X 99.5% 99.9%
Patient 3 10X 96.7% 98.5%
Patient 4 6X 92.9% 98.6%
Patient 5 6X 99.0% 100.0%
Patient 6 6X 99.8% 100.0%
Patient 7 10X 99.8% 100.0%
Patient 8 6X 97.2% 97.3%
*The gamma passing rates for absolute dose distribution. †The 
gamma passing rates for relative dose distribution.
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was suggested by the American Association of Physicists in 
Medicine (AAPM) task group (TG) 119.10-12) In this regards, 
our patient-specific QA summary turned out to be clini-
cally acceptable even after the target replacement with fine 
adjustments. 
Another consideration is about radiation safety. The pos-
sible Linac target activation should be carefully surveyed. 
The removed target became a radioactive material due to 
prolonged exposure to the radiation, and we measured 
the replaced target with a survey meter (TRACERCOTM 
T402, Johnson Matthey, Pasadena, TX, USA). Before lead 
shielding, the instantaneous dose rate (IDR) was 1.20 μSv/
h near the target and 0.39 μSv/h at 1 m away from the tar-
get. After lead shielding, the IDR dropped down to 0.22 
μSv/h and decreased to 0.13 μSv/h after the lead-shielded 
target was stored in a radioactive waste container. Even 
with confirmation of background IDR level, we determined 
the periodic IDR measurement to monitor and prevent the 
possible hazardous situation.
We verified the fundamental beam parameters that 
agreed within 1% with the reference beam data after the 
target assembly replacement. The gamma analysis results 
for eight patients with relative and absolute dose distribu-
tion were also acceptable.13) This study suggests the pre-
vention of the target assemblies; the beam output should 
be verified with daily routine, and furthermore, calibrated 
under the recommended conditions, i.e., depth at dose 
maximum not with 10 cm.14)
Conclusion
We experienced the photon beam degradation due to the 
target burning, and thereby the target replacement and the 
beam verification were performed. We concluded that the 
patient treatment could be appropriately performed after 
the target replacement owing to guaranteed mandatory 
beam characteristics, and acceptable patient-specific QA 
results. We suggest the compliance with the manufactur-
er’s recommendation for output calibration, i.e. at a depth 
of maximum dose, not at 10 cm, and the number of IMRT 
treatments should be controlled for the machine perfor-
mance. When experiencing the undesired target puncture, 
beam output, profiles, and energy should be finely adjusted 
to the reference beam data, and patient-specific QA should 
be performed for validation. We also recommended that 
the replaced target should be kept in radiation shielded 
space, and the activation level should be recorded in a pe-
riodic routine.
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